ADC Therapeutics SA
PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
Last updated:
Abstract:
The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
Status:
Application
Type:
Utility
Filling date:
28 Aug 2020
Issue date:
22 Apr 2021